EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target

William W Feng iD, Hannah T Zuppe, Manabu Kurokawa iD

Cells · 11.06.2023 · 12 (12) · 1605

DOI: 10.3390/cells12121605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 11.06.2023. Verfasst von William W Feng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Ovarian Neoplasms. Die Arbeit wurde bisher 104-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cluster of differentiation 36 (CD36) is a cell surface scavenger receptor that plays critical roles in many different types of cancer, notably breast, brain, and ovarian cancers. While it is arguably most well-known for its fatty acid uptake functions, it is also involved in regulating cellular adhesion, immune response, and apoptosis depending on the cellular and environmental contexts. Here, we discuss the multifaceted role of CD36 in cancer biology, such as its role in mediating metastasis, drug resistance, and immune evasion to showcase its potential as a therapeutic target. We will also review existing approaches to targeting CD36 in pre-clinical studies, as well as discuss the only CD36-targeting drug to advance to late-stage clinical trials, VT1021. Given the roles of CD36 in the etiology of metabolic disorders, such as atherosclerosis, diabetes, and non-alcoholic fatty liver disease, the clinical implications of CD36-targeted therapy are wide-reaching, even beyond cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseOvarian NeoplasmsFemaleHumansFatty AcidsCD36 Antigens

Stichwörter der Autor:innen

cancer stem cellsdrug resistanceimmune evasionlipid metabolismmetastasistargeted therapytumor microenvironment

Substanzen

Fatty AcidsCD36 Antigens

Autor:innen und Institutionen

  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Department of Medicine, Harvard Medical School, Boston, MA 02215, USA.
  • School of Biomedical Sciences, Kent State University, Kent, OH 44240, USA.
  • Department of Biological Sciences, Kent State University, Kent, OH 44240, USA.

ORCID-Profile: William W Feng, Manabu Kurokawa

Förderung

  • NCI NIH HHS
  • NIH HHS
  • NIA NIH HHS
  • NIH

Zitieren

APA

Feng, W. W., Zuppe, H. T., & Kurokawa, M. (2023). The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target. Cells, 12(12), 1605. https://doi.org/10.3390/cells12121605

Vancouver

Feng WW, Zuppe HT, Kurokawa M. The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target. Cells. 2023;12(12):1605. doi:10.3390/cells12121605

BibTeX
@article{Feng2023,
  author = {Feng, William W and Zuppe, Hannah T and Kurokawa, Manabu},
  title = {The Role of CD36 in Cancer Progression and Its Value as a Therapeutic Target},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {1605},
  doi = {10.3390/cells12121605}
}
Kostenlos starten →